Harvard Bioscience, Inc.
HBIO
$7.08
$0.111.58%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 11.13% | -4.68% | -3.34% | -6.28% | -11.46% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 11.13% | -4.68% | -3.34% | -6.28% | -11.46% |
| Cost of Revenue | 13.23% | -11.25% | -8.94% | -6.90% | -9.74% |
| Gross Profit | 9.51% | 0.49% | 0.84% | -5.83% | -12.75% |
| SG&A Expenses | 13.82% | -1.17% | -21.94% | -16.76% | -20.58% |
| Depreciation & Amortization | -29.43% | -29.31% | -32.38% | -35.91% | -12.70% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 11.00% | -7.28% | -15.30% | -14.02% | -14.94% |
| Operating Income | -6.62% | 42.18% | 624.40% | 114.45% | 63.00% |
| Income Before Tax | -28.48% | 93.49% | -643.05% | 74.75% | 31.28% |
| Income Tax Expenses | -50.00% | 125.77% | -162.41% | -68.81% | 107.93% |
| Earnings from Continuing Operations | -27.52% | 93.20% | -15,916.67% | 74.36% | 22.04% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -27.52% | 93.20% | -15,916.67% | 74.36% | 22.04% |
| EBIT | -6.62% | 42.18% | 624.40% | 114.45% | 63.00% |
| EBITDA | -28.28% | 1,225.81% | 110.68% | 1,207.50% | 678.91% |
| EPS Basic | -24.83% | 93.29% | -15,668.29% | 74.90% | 23.47% |
| Normalized Basic EPS | -22.84% | -10.14% | -443.96% | 75.35% | 22.53% |
| EPS Diluted | -23.65% | 93.26% | -15,668.29% | 72.75% | 22.75% |
| Normalized Diluted EPS | -22.84% | -10.14% | -450.29% | 75.35% | 22.53% |
| Average Basic Shares Outstanding | 2.17% | 1.43% | 2.16% | 2.16% | 1.87% |
| Average Diluted Shares Outstanding | 2.17% | 1.43% | 0.33% | 2.16% | 1.87% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |